Anti-Gout Drug May Decrease Risk of Colon Cancer

September 6, 2011 by Lynn.

Allopurinol, a relatively inexpensive gout medication that has been on the market for more than 20 years, may have some activity against colorectal adenomas, or polyps, according to two separate studies. Most colorectal cancer develops from adenomatous polyps.

A large study in Israel showed that patients using allopurinol for gout had a lower risk of colorectal cancer than a control group not taking allopurinol. A second study in Italy appeared to confirm that the gout medicine protects against colon carcinogenesis. To read the full article on ScienceDaily, CLICK HERE.<

Filed under: Cancer, Gout Medications.

Tags: anti-gout drug, gout medication, allopurinol for gout, gout medicine, allopurinol,, colchicine.

There are no comments for now. Leave your comments.

Gout Drug Colchicine Proves a Cancer

September 15, 2011 by Estella.

from squirrelcowdog
from squirrelcowdog
A new cancer drug based on the gout drug colchicine is proving to be a powerful cancer drug capable of quickly killing malignant tumors. The new drug, called ICT2588 for now, is being referred to as a "smart bomb" because it can directly target a tumor without harming surrounding healthy tissue.

Both the gout medication colchicine and the experimental ICT2588 are derived from the autumn crocus, or meadow saffron. Colchicine (brand name Colcrys) has been widely and successfully used to treat gouty arthritis for centuries. Colchicine was known to have the potential to fight cancer, but can be toxic at high doses. This experimental modified form is harmless to healthy tissue, but toxic to tumor blood vessels.

Scientists the University of Bradford in England found a way of keeping ICT2588 non-toxic until it comes into contact with a protein released by tumors, MMP1. Tumors release MMP to cut a path into surrounding tissue where they can develop new blood vessels. "Our novel delivery system uses the presence of this active MMP to activate the drug, which attacks and breaks down cancer blood vessels, destroying the tumor's lifeline," explains Professor Lawrence Patterson, head of research team that developed ICT2588.

"What is also novel about our approach is that we are effectively targeting the blood supply of the tumor," says Patterson, "If you can starve the tumor of that blood supply, then you can cut off its ability to grow and to move around the body."

ICT2588 was so successful in destroying breast, prostrate and bowel cancers in mice that over half the mice went into remission after just one treatment. There were no ill effects. Although ICT2588 has only been tested in animals so far, researchers are hoping to test it in humans within two years, and possibly even within 18 months. The drug is expected to be effective against all kinds of solid tumors.

Filed under: Cancer.

Tags: colchicine, gout drug colchicine, gout medication, brand name colcrys, gouty arthritis .

There are 1 comment(s). Leave your comments.

New Research Shows Colchicine May Help Fight Cancer

February 3, 2012 by Shelly.

Treating Cancer with minimal damage to the patient's health is a constant battle for researchers and scientists developing new cancer fighting drugs. Finding a drug that targets only the infected cells in our body and does not harm otherwise healthy tissue is not an easy quest, but is the driven work of Professor Laurence Patterson, Director of the institute of Cancer Therapeutics at the University of Bradford, and his team.

Patterson's team are developing a new therapy that is based on the chemical Colchicine; a drug that is currently being used most commonly to treat gout.

Colchicine - a compound derived from the Autumn Crocus, the team believes that this is the first attempt at removing existing blood vessel supply to a tumour. Using an enzyme, only found in diseased tissue as a trigger means that it can also target secondary tumours caused by the cancer spreading through the body.

Their starting point was a batch of Matrix Metalloproteinases called MMP14, which had been identified in tumour tissue. This enzyme breaks down the proteins in surrounding healthy tissue and allows the tumour to proliferate. When the tiny molecules of the drug meet the MMP14 they combine to activate the drug.

Destroying Cancer's lifeline
The tumour grows by getting its nutrients from the body. So if you can destroy the vasculator that the tumour has, then you starve it of oxygen and nutrients. Professor Patterson explains, 'we knew there were these disrupting agents but they weren't targeted. The ones that were being trialled would work where they were absorbed so one of the areas where their toxicity was high was the heart. These drugs hadn't progressed because of this. That's what's so exciting about what we have achieved. Every tumour that we have looked at expresses this enzyme MMP14 and the reason why they all express it is because all tumours that are confined within their original normal tissue environment need to break out of that environment, it's an enzyme that has benefit to all tumour types.'

Clinical trial
Although the chemical, Colchicine is a natural derivative, the team are manufacturing it in the laboratory. The have established the concept and provided supporting evidence for the research, so once that funding has been established, they will begin the next phase of to develop the drug and begin clinical trial.

The beauty of this drug, Patterson says is its compatibility with conventional treatments such as chemotherapy. Taking into account the resistant nature of tumours, Colchicine promises another weapon in the body's battle, cutting off the blood supply that allows the cancer to flourish, so even an aggressive cancer could be neutralised.

Filed under: Colchicine Use, Cancer.

Tags: colchicine, research on colchcine, colchicine for cancer, colchicine therapy, colchicine drug,

There are no comments for now. Leave your comments.
Most Recent Posts